Skye Bioscience - SKYE Forward P/E Multiple

Corporate company logo of Skye Bioscience, Inc. (SKYE)

The historical price chart for Skye Bioscience, Inc. (SKYE) illustrates the P/E ratio trend, which currently stands at 0.00. Global sanctions and logistical complexities are hindering the development of glaucoma treatments. Meanwhile, the business is pivoting its R&D toward weight loss, testing a new drug in the US designed to target specific receptors.

Future Price to Earnings Multiple: Skye Bioscience (SKYE) for 04/12/2024 - 11/16/2026

Analytical breakdowns and data insights for company Skye Bioscience Inc. (SKYE)

- stock quotes and analyst forecast:
Comprehensive company analysis:skyebioscience.com SKYE
Signature product of Skye Bioscience

The market views Skye Bioscience, Inc. (SKYE) as a high-risk asset with growth potential. This metric compares the current share price with expected earnings to determine the premium paid for future success. By analyzing the forward P/E ratio of Skye Bioscience, Inc. (SKYE) on GURU.Markets, an investor can gauge the value of future capitalization. For the biopharmaceutical sector, this reflects confidence in the commercialization of non-psychoactive obesity drugs. This tool characterizes the stock as a speculative growth play.